
Opinion|Videos|October 21, 2024
Balancing Efficacy Outcomes With Tolerability and Quality of Life in First-Line mRCC Treatment Decisions
Author(s)Rana R. McKay, MD
Panelists discuss how they balance efficacy outcomes like overall survival and progression-free survival against tolerability and quality of life considerations when making decisions about first-line treatment for metastatic renal cell carcinoma patients.
Advertisement
Episodes in this series

- How do efficacy outcomes, such as overall survival and progression-free survival, compare with tolerability and quality of life in your decision-making process for first-line metastatic renal cell carcinoma treatment?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















